person · Reporting owner

Chiniara Ellen

Disclosed activity across 4 companies

Tapewire entity: 70329
SEC CIK: 0001398764

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Compass Therapeutics, Inc.CMPX · Entity 5614	Director	January 02, 2026	January 05, 2026
Kymera Therapeutics, Inc.KYMR · Entity 3545	Chief Legal Officer	March 03, 2025	March 03, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Compass Therapeutics, Inc.

Report date January 02, 2026 · Filed January 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02	Direct	90,000	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.

Kymera Therapeutics, Inc.

Report date March 03, 2025 · Filed March 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	80,085	Ending reported balance After 2025-03-03 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2025-03-03 · Grant · Acquired 27,500 · Balance 82,326 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Row 2 · 2025-03-03 · Sale · Disposed 1,833 · Balance 80,493 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 408 · Balance 80,085 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.17 · Expires 2035-03-02	Direct	55,000	Reported balance After 2025-03-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-03-03 · Grant · Acquired 55,000 · Balance 55,000 F5: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.

F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALERE INC.

Report date October 03, 2017 · Filed October 03, 2017

Section 16 reporting ended · disclosed 2017-10-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-10-03 transaction · row 1 1 source row Row 1 · 2017-10-03 · Disposition to issuer · Disposed 32,764 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.58	Direct	Reported balance After 2017-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-10-03 · Disposition to issuer · Disposed 8,331 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.01	Direct	Reported balance After 2017-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-03 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.06	Direct	Reported balance After 2017-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.47	Direct	Reported balance After 2017-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-10-03 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.42	Direct	Reported balance After 2017-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-10-03 · Disposition to issuer · Disposed 5,250 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.43	Direct	Reported balance After 2017-10-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-10-03 · Disposition to issuer · Disposed 975 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.68	Direct	Reported balance After 2017-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-10-03 · Disposition to issuer · Disposed 11,788 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.74	Direct	Reported balance After 2017-10-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-10-03 · Disposition to issuer · Disposed 1,500 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-10-03 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-10-03 · Disposition to issuer · Disposed 19,470 · Balance 0 F3: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F3: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

ALEXION PHARMACEUTICALS, INC.

Report date July 21, 2021 · Filed July 23, 2021

Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2021-07-21 transaction · row 1 1 source row Row 1 · 2021-07-21 · Disposition to issuer · Disposed 116,850 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2026 Filed Jan 5, 2026 21:33 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	90,000	$0.00 Strike: $5.17	$0.00	Disclosure SEC source: 0001171843-26-000057 · ownership.xml · derivative · entry 1 Chiniara Ellen · CIK 0001398764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders. Read SEC document
March 03, 2025 Filed Mar 3, 2025 23:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	55,000	$0.00 Strike: $30.17	$0.00	Disclosure SEC source: 0000950170-25-031148 · ownership.xml · derivative · entry 4 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-03-02 F5 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document
March 03, 2025 Filed Mar 3, 2025 23:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	408	$31.00	$12,649.88	Disclosure SEC source: 0000950170-25-031148 · ownership.xml · nonDerivative · entry 3 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,085 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 03, 2025 Filed Mar 3, 2025 23:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	1,833	$30.33	$55,589.57	Disclosure SEC source: 0000950170-25-031148 · ownership.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,493 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 03, 2025 Filed Mar 3, 2025 23:30 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantCommon Stock	27,500	$0.00	$0.00	Disclosure SEC source: 0000950170-25-031148 · ownership.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,326 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document
February 11, 2025 Filed Feb 13, 2025 22:09 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001171843-25-000826 · ownership.xml · derivative · entry 1 Chiniara Ellen · CIK 0001398764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 11, 2025. Read SEC document
January 06, 2025 Filed Jan 6, 2025 22:00 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	3,129	$41.75	$130,644.82	Disclosure SEC source: 0000950170-25-002266 · ownership.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,826 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $41.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: This number includes 1,203 shares and 792 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024 and December 1, 2024, respectively. Read SEC document
March 01, 2024 Filed Mar 4, 2024 23:15 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	130,531	$0.00 Strike: $43.50	$0.00	Disclosure SEC source: 0000950170-24-025093 · ownership.xml · derivative · entry 2 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,531 Underlying: Common Stock · 130,531 shares Expires 2034-02-28 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document
March 01, 2024 Filed Mar 4, 2024 23:15 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantCommon Stock	21,755	$0.00	$0.00	Disclosure SEC source: 0000950170-24-025093 · ownership.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,960 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document
February 09, 2024 Filed Feb 14, 2024 17:01 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0001171843-24-000793 · ownership.xml · derivative · entry 1 Chiniara Ellen · CIK 0001398764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 9, 2024. Read SEC document
January 04, 2024 Filed Jan 5, 2024 22:15 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	SaleCommon Stock	3,295	$22.58	$74,415.60	Disclosure SEC source: 0000950170-24-002536 · ownership.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,205 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $22.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 08, 2023 Filed Feb 9, 2023 21:31 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.93	$0.00	Disclosure SEC source: 0001171843-23-000855 · ownership.xml · derivative · entry 1 Chiniara Ellen · CIK 0001398764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-07 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 8, 2023. Read SEC document
January 03, 2023 Filed Jan 4, 2023 21:35 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantStock Option (Right to Buy) · Derivative	225,000	$0.00 Strike: $24.84	$0.00	Disclosure SEC source: 0000899243-23-000630 · doc4.xml · derivative · entry 2 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-01-02 F2 · derivative.exercise_date: 25% of the shares underlying this stock option shall vest on January 3, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. Read SEC document
January 03, 2023 Filed Jan 4, 2023 21:35 UTC	Kymera Therapeutics, Inc. KYMR · Entity 3545	GrantCommon Stock	37,500	$0.00	$0.00	Disclosure SEC source: 0000899243-23-000630 · doc4.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following January 3, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document
April 26, 2022 Filed Apr 28, 2022 17:29 UTC	Compass Therapeutics, Inc. CMPX · Entity 5614	GrantStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $1.51	$0.00	Disclosure SEC source: 0001171843-22-002945 · ownership.xml · derivative · entry 1 Chiniara Ellen · CIK 0001398764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: This option vests in substantially equal monthly installments over four years. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:40 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerCommon Stock, par value $.0001 per share	116,850	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000068 · wf-form4_162707282278233.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Read SEC document
July 14, 2021 Filed Jul 16, 2021 16:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	27,657	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000053 · wf-form4_162646839305869.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,850 F2 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan. Read SEC document
July 14, 2021 Filed Jul 16, 2021 16:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	26,812	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000053 · wf-form4_162646839305869.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,193 F1 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan. Read SEC document
February 28, 2021 Filed Mar 2, 2021 17:57 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	19,321	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000027 · wf-form4_161472583224710.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,381 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:02 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	2,988	$157.96	$471,984.48	Disclosure SEC source: 0000899866-20-000091 · wf-form4_160832896191217.xml · nonDerivative · entry 3 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,004 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:02 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	16,925	$157.96	$2,673,473.00	Disclosure SEC source: 0000899866-20-000091 · wf-form4_160832896191217.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,992 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:02 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	37,965	$0.00	$0.00	Disclosure SEC source: 0000899866-20-000091 · wf-form4_160832896191217.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,917 F1 · shares: Shares acquired on vesting of Performance Stock Units previously granted on February 28, 2018 under the 2017 Stock Incentive Plan. Read SEC document
December 15, 2020 Filed Dec 18, 2020 17:02 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	56	$95.53	$5,349.68	Disclosure SEC source: 0000899866-20-000091 · wf-form4_160832896191217.xml · nonDerivative · entry 4 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,060 F4 · shares: In accordance with the Alexion ESPP, these shares were purchased (for the ESPP purchase period from July 1, 2020 to December 15, 2020) based on 85% of the share price on July 1, 2020. Read SEC document
March 02, 2020 Filed Mar 3, 2020 18:31 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,263	$90.54	$114,352.02	Disclosure SEC source: 0000899866-20-000026 · wf-form4_158327828887030.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,898 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 28, 2020 Filed Mar 3, 2020 18:31 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	10,200	$0.00	$0.00	Disclosure SEC source: 0000899866-20-000026 · wf-form4_158327828887030.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,161 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
December 15, 2019 Filed Mar 3, 2020 18:31 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	54	$93.86	$5,068.44	Disclosure SEC source: 0000899866-20-000026 · wf-form4_158327828887030.xml · nonDerivative · entry 3 Chiniara Ellen · CIK 0001398764 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,952 F4 · shares: In accordance with the Alexion ESPP, these shares were purchased (for the ESPP purchase period from June 30, 2019 to December 15, 2019) based on 85% of the closing price of the Issuer's common stock on December 15, 2019. Read SEC document
February 28, 2019 Filed Mar 4, 2019 17:43 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	633	$132.92	$84,138.36	Disclosure SEC source: 0000899866-19-000042 · wf-form4_155173940527059.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,711 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $134.74. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 28, 2019 Filed Mar 5, 2019 20:14 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	8,250	$0.00	$0.00	Disclosure SEC source: 0000899866-19-000046 · wf-form4_155183486992229.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,961 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:01 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	8,344	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000062 · wf-form4_152002809787521.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,344 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerRestricted Stock Units · Derivative	19,470	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 10 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,470 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	1,500	Not disclosed Strike: $36.74	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 9 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	11,788	Not disclosed Strike: $25.68	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 8 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,788 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	975	Not disclosed Strike: $25.43	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 7 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 975 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,250	Not disclosed Strike: $37.42	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 6 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,250 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	35,000	Not disclosed Strike: $45.47	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 5 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $26.06	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 4 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,000	Not disclosed Strike: $38.01	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 3 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	8,331	Not disclosed Strike: $35.58	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · derivative · entry 2 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,331 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:31 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerCommon Stock	32,764	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-17-001779 · es1701004_4-chiniara.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). Read SEC document
August 31, 2017 Filed Sep 5, 2017 19:43 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionRestricted Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0001179110-17-012033 · edgar.xml · derivative · entry 3 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: On August 31, 2014, the reporting person was granted 20,000 restricted stock units, which vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17). F2 · derivative.expiration_date: On August 31, 2014, the reporting person was granted 20,000 restricted stock units, which vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17). Read SEC document
August 31, 2017 Filed Sep 5, 2017 19:43 UTC	ALERE INC. ALR · Entity 172772	Tax withholdingCommon Stock	2,163	$49.46	$106,981.98	Disclosure SEC source: 0001179110-17-012033 · edgar.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,764 Read SEC document
August 31, 2017 Filed Sep 5, 2017 19:43 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionCommon Stock	6,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-012033 · edgar.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. Read SEC document
February 16, 2017 Filed Feb 21, 2017 18:08 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionRestricted Stock Units · Derivative	7,236	$0.00	$0.00	Disclosure SEC source: 0001179110-17-002822 · edgar.xml · derivative · entry 6 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,470 Underlying: Common Stock · 7,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F3 · derivative.exercise_date: On February 16, 2016 the reporting person was granted 21,706 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19). F3 · derivative.expiration_date: On February 16, 2016 the reporting person was granted 21,706 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19). Read SEC document
February 16, 2017 Filed Feb 21, 2017 18:08 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionRestricted Stock Units · Derivative	2,500	$0.00	$0.00	Disclosure SEC source: 0001179110-17-002822 · edgar.xml · derivative · entry 5 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: On February 16, 2016 the reporting person was granted 7,500 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19). F2 · derivative.expiration_date: On February 16, 2016 the reporting person was granted 7,500 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19). Read SEC document
February 16, 2017 Filed Feb 21, 2017 18:08 UTC	ALERE INC. ALR · Entity 172772	Tax withholdingCommon Stock	2,432	$40.40	$98,252.80	Disclosure SEC source: 0001179110-17-002822 · edgar.xml · nonDerivative · entry 4 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,260 Read SEC document
February 16, 2017 Filed Feb 21, 2017 18:08 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionCommon Stock	7,236	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-002822 · edgar.xml · nonDerivative · entry 3 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. Read SEC document
February 16, 2017 Filed Feb 21, 2017 18:08 UTC	ALERE INC. ALR · Entity 172772	Tax withholdingCommon Stock	811	$40.40	$32,764.40	Disclosure SEC source: 0001179110-17-002822 · edgar.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,456 Read SEC document
February 16, 2017 Filed Feb 21, 2017 18:08 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionCommon Stock	2,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-002822 · edgar.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. Read SEC document
November 30, 2016 Filed Feb 15, 2017 17:58 UTC	ALERE INC. ALR · Entity 172772	OtherCommon Stock	238	$33.73	$8,027.26	Disclosure SEC source: 0001179110-17-002459 · edgar.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,767 F1 · kind: These securities were acquired under the Alere Inc. Employee Stock Purchase Plan. This transaction, which is exempt from Section 16(b) by virtue of Rule 16b-3(c), is being voluntarily reported. Read SEC document
October 14, 2016 Filed Oct 18, 2016 17:40 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	5,000	Not disclosed Strike: $37.74	Not disclosed	Disclosure SEC source: 0001179110-16-030772 · edgar.xml · derivative · entry 11 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2016-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This derivative security does not have a price. F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning October 16, 2007. F4 · derivative.expiration_date: The Options were scheduled to expire on October 15, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.